AbbVie’s JUVMO Approval Puts 41% Undervaluation Thesis in Focus
AbbVie’s JUVMO approval strengthens its pipeline narrative, while Simply Wall St’s 41% undervaluation estimate remains a forecast—not confirmed market performance.
onsemi Raises Synaptics Offer to $123 a Share as Semiconductor M&A Accelerates
onsemi’s revised $123-per-share cash offer for Synaptics highlights semiconductor valuation debates …
Q32 Bio Slides 13.2% as Oppenheimer Defends Rating Despite Bempikibart Data Concerns
Q32 Bio fell 13.2% as investors questioned bempikibart’s efficacy, while Oppenheimer maintained its …
AbbVie’s Rinvoq Vitiligo Data Set Up Q4 FDA Catalyst for ABBV Investors
Rinvoq’s promising vitiligo results and expected Q4 2026 FDA decision add a potential growth catalys…
Wave Life Sciences Shares Rise as FDA Confirms Registrational Pathway for WVE-006
FDA alignment on WVE-006 trial design gives Wave Life Sciences a clearer regulatory path, but execut…
Q32 Bio Stock Falls 13.2% as Oppenheimer Stands by Rating Despite Trial-Data Concerns
Q32 Bio sharply underperformed biotech peers as investors questioned bempikibart efficacy, while Opp…
PolyPid Regains European Rights to D-PLEX100: What It Means for PYPD’s Strategy
PolyPid’s return of European rights to D-PLEX100 may expand partnership options and reshape the valu…
Outlook Therapeutics Seeks CMS Reimbursement Code Ahead of LYTENAVA Launch
Outlook Therapeutics’ CMS reimbursement application marks a key commercial milestone for LYTENAVA an…
Merck’s Positive Phase 2 HS Data Offer a Glimpse Beyond Oncology
Merck’s positive Phase 2 hidradenitis suppurativa data could broaden investor focus beyond its oncol…
Praxis Precision Medicine Options Activity Builds Ahead of Two FDA Decisions
Praxis Precision Medicine is seeing elevated options activity as traders position around two FDA dec…